Clinical trials: Newly Diagnosed Breast Cancer
Leptomeningeal Carcinomatosis, Leptomeningeal Metastases
ANG1005 in Leptomeningeal Disease From Breast Cancer
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated…
- Conditions
- Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer
- Trial name
- ANGLeD (NCT03613181)
- Testing
- ANG1005, Physician's Best Choice
- Volunteers
- 150 people
- Sponsor
- Angiochem Inc
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT01409811
- Testing
- zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Neoplasms, Breast
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
This Study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer.
- Trial name
- NCT00111787
- Testing
- Lapatinib, Paclitaxel
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer
This is a study to assess the feasibility and acceptability of a novel decision aid (DA) in a newly diagnosed, early-stage breast cancer population.
- Trial name
- NCT06813053
- Testing
- Decision Aid (DA), Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.
- Trial name
- NCT00463034
- Testing
- microarray analysis, polymerase chain reaction, polymorphism analysis
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- University of Sheffield
Male Breast Carcinoma, Recurrent Breast Carcinoma
Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
This pilot clinical trial studies how well pazopanib hydrochloride works in treating patients with breast cancer that is newly diagnosed or has come back at or near the same place as the original tumor and can be removed by…
- Conditions
- Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT00450879
- Testing
- Pazopanib Hydrochloride, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Hereditary Breast Cancer
Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer
The overall purpose of the study is to evaluate a method for offering mutation analysis of BRCA1 and BRCA2 to all patients with newly diagnosed breast cancer, regardless of age at diagnosis and family history.
- Trial name
- BRCAsearch (NCT02557776)
- Testing
- Germline genetic testing of BRCA1 and BRCA2
- Where
- 2 sites in Sweden
- Volunteers
- 542 people
- Sponsor
- Lund University
Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma
This study is for adult females who have been newly diagnosed with breast cancer that includes surgery as part of standard cancer treatment.
- Trial name
- NCT01816555
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Breast Cancer
Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients
Comparison of Preoperative Automated Breast Ultrasound (ABUS) and magnetic resonance imaging (MRI) in Newly Diagnosed Breast Cancer Patients.
- Trial name
- ABUS (NCT02488187)
- Testing
- ABUS
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer, Cognitive/Functional Effects
Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer
RATIONALE: Gathering health information from older patients undergoing chemotherapy may help doctors plan better treatment and improve the quality of life for these patients.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00873600
- Testing
- chemotherapy, medical chart review, questionnaire administration
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Psychosocial Adaptation
The Effect of Roy Adaptation Model-Based Nursing Interventions on Psychological Resilience and Psychosocial Adjustment in Newly Diagnosed Breast Cancer Patients: A Randomized Controlled Trial
Today, cancer has become a multifaceted problem whose diagnosis and treatment should be handled multidisciplinarily. In addition to being a medical-physical disease, cancer is a chronic phenomenon that involves many mental and…
- Conditions
- Breast Cancer, Psychosocial Adaptation, Psychological Resilience
- Trial name
- NCT06910917
- Testing
- Roy Adaptation-Based Nursing Interventions
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Aytuğ Türk
Early Triple Negative Breast Cancer
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC).
- Trial name
- NCT06829199
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 2 sites in United States, Taiwan
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Breast Neoplasms
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
The purpose of this research study is to find the lowest dose of the cancer drug parsaclisib that has an effect on the type of breast cancer a participant has. Researchers are looking at how Parsaclisib affects the immune system.
- Conditions
- Breast Cancer, Breast Neoplasms, Triple Negative Breast Cancer, HER2-positive Breast Cancer
- Trial name
- LCCC1820 (NCT04142554)
- Testing
- Parsaclisib
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Neoplasm Malignant Female
Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)
This is a multicenter hospital-based prospective cohort study conducted in institutions with known expertise in performing oocytes/embryo freezing for fertility preservation.
- Trial name
- fAMHOPE (NCT04289805)
- Testing
- Letrozole, standard-stimulated cohort
- Where
- 6 sites in Belgium, France and 1 more
- Volunteers
- 96 people
- Sponsor
- Erasme University Hospital
Invasive Ductal Carcinoma, Lobular Breast Carcinoma
Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy
A PET scan drop less than 20% in SUVs or below a certain absolute SUV value after the first course of neoadjuvant chemotherapy can predict pathological response, and could in the future lead to an early surgical intervention.
- Conditions
- Invasive Ductal Carcinoma, Lobular Breast Carcinoma, Inflammatory Breast Carcinoma
- Trial name
- PETBreast (NCT01038258)
- Testing
- PET scan after course 1 and surgery after 8 courses
- Where
- Puerto Rico
- Volunteers
- 80 people
- Sponsor
- Auxilio Mutuo Cancer Center
Breast Cancer
Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00096343
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Alabama at Birmingham
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Breast Cancer
Efficacy of Digital Breast Tomosynthesis + Standard 2- Dimensional Mammography in Breast Cancer
The purpose of this study is to determine if a 3-dimensional mammogram (DBT) may provide additional information to evaluate the extent of disease and additional findings that would aid in staging a new breast cancer patient.
- Trial name
- NCT03190083
- Testing
- 2-dimensional mammogram, digital breast tomosynthesis (DBT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Newly Diagnosed Breast Cancer
Circulating miRNAs.
To identify a panel of circulating miRNA markers which could help identify those breast cancer patients who are most likely to respond well to neoadjuvant and adjuvant chemotherapy, and indeed serve as an overall prognostic…
- Conditions
- Breast Cancer, Newly Diagnosed Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01722851
- Where
- 7 sites in Ireland
- Volunteers
- 255 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
- Trial name
- NCT00754312
- Testing
- SNDX-275
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals